RT Journal Article
T1 Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
A1 Molina, David
A1 Pérez-Beteta, Julián
A1 Martínez-González, Alicia
A1 Sepúlveda, Juan M
A1 Peralta, Sergi
A1 Gil-Gil, Miguel J
A1 Reynes, Gaspar
A1 Herrero, Ana
A1 De Las Peñas, Ramón
A1 Luque, Raquel
A1 Capellades, Jaume
A1 Balaña, Carmen
A1 Pérez-García, Víctor M
K1 Inhibidores de la angiogénesis
K1 Bevacizumab
K1 Biomarcadores
K1 Dacarbazina
K1 Diagnóstico por imagen
K1 Glioblastoma
K1 Estudios prospectivos
AB BACKGROUNDAntiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy.METHODS40 patients from the randomized GENOM009 study complied the inclusion criteria (quality of images, clinical data available). Of those, 23 patients received first line temozolomide (TMZ) for eight weeks and then concomitant radiotherapy and TMZ. 17 patients received BVZ+TMZ for seven weeks and then added radiotherapy to the treatment. Clinical variables were collected, tumors segmented and several geometrical measures computed including: Contrast enhancing (CE), necrotic, and total volumes; equivalent spherical CE width; several geometric measures of the CE 'rim' geometry and a set of image texture measures. The significance of the results was studied using Kaplan-Meier and Cox proportional hazards analysis. Correlations were assessed using Spearman correlation coefficients.RESULTSKaplan-Meier and Cox proportional hazards analysis showed that total, CE and inner volume (p = 0.019, HR = 4.258) and geometric heterogeneity of the CE areas (p = 0.011, HR = 3.931) were significant parameters identifying response to BVZ. The group of patients with either regular CE areas (small geometric heterogeneity, median difference survival 15.88 months, p = 0.011) or those with small necrotic volume (median survival difference 14.50 months, p = 0.047) benefited substantially from BVZ.CONCLUSIONImaging biomarkers related to the irregularity of contrast enhancing areas and the necrotic volume were able to discriminate GBM patients with a substantial survival benefit from BVZ. A prospective study is needed to validate our results.
PB Public Library of Science
YR 2016
FD 2016-08-24
LK http://hdl.handle.net/10668/2476
UL http://hdl.handle.net/10668/2476
LA en
NO Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, et al. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE. 2016; 11(8):e0161484
NO Journal Article;
DS RISalud
RD Apr 7, 2025